Medication Use in Systemic Lupus Erythematosus

@article{Bernatsky2011MedicationUI,
  title={Medication Use in Systemic Lupus Erythematosus},
  author={Sasha Bernatsky and Christine A. Peschken and Paul R. Fortin and Christian A. Pineau and Murray B. Urowitz and Dafna D. Gladman and Janet E. Pope and Marie Hudson and Michel Zummer and C. Douglas Smith and Hector O Arbillaga and Ann E. Clarke},
  journal={The Journal of Rheumatology},
  year={2011},
  volume={38},
  pages={271 - 274}
}
Objective. To evaluate factors affecting therapeutic approaches used in clinical practice for the management of systemic lupus erythematosus (SLE), in a multicenter cohort. Methods. We combined data from 10 clinical adult SLE cohort registries in Canada. We used multivariate generalized estimating equation methods to model dichotomized outcomes, running separate regressions where the outcome was current exposure of the patient to specific medications. Potential predictors of medication use… 
View on Publisher
jrheum.org
10 Citations
Methods Citations
1

10 Citations

Citation Type

Citation Type

Treatment pathways in an inception lupus cohort over the first three years
TLDR
Patients with new onset systemic lupus erythematosus who used corticosteroids either at baseline, at any time in the three year study or in high cumulative doses had the highest average disease activity scores over the same time frame and had a significant fall in SLEDAI-2K scores.
Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark
TLDR
Time to start of AM treatment following SLE diagnosis could be further reduced, especially among patients with renal disease, but the results showed that treatment practice in recent years has changed toward initiating AM treatment earlier.
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort.
TLDR
Longitudinal modelling of an SLE cohort confirmed relationships between risk factors and long-term outcomes in SLE and can be used to estimate the effectiveness and cost-effectiveness of new treatments.
Patterns of medication use before, during and after pregnancy in women with systemic lupus erythematosus: a population-based cohort study
TLDR
These population-based data show frequent discontinuation of medications, particularly antimalarials, in SLE pregnancies, and suggest the importance of educating women with SLE who are pregnant or planning to become pregnant on the benefits and risks of medications during pregnancy.
Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis
TLDR
As AMs reduce disease damage and improve survival in patients with SLE, their results demonstrate an opportunity to target future efforts to improve prescribing rates among multi-specialty providers.
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006
TLDR
Epratuzumab treatment produced clinically meaningful and sustained improvements in PGA, PtGA and HRQOL and reductions in corticosteroid doses and was maintained in SL0006 over ∼2 years.
A population-based assessment of live births in women with systemic lupus erythematosus
TLDR
After diagnosis, women with SLE have substantially fewer live births than the general population.
Reflections on Lupus 2013: butterflies, wolves and prophecies
TLDR
This overview summarizes some of the origins of the First International Congress held in Calgary, Canada in 1986, predictions offered by past Congress Presidents, and a perspective on the trends in autoantibody testing, which remains one of the key approaches to the early and accurate diagnosis of SLE.
Targeting IL-6 promoter polymorphism −174G/C should be dependent on ethnicity

References

SHOWING 1-10 OF 22 REFERENCES
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
TLDR
AMS is associated with the presence of damage and CAD and it is not associated with AVN.
Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease.
TLDR
Although disease activity tends to be lower in these patients, they tend to accrue more damage and experience higher mortality than patients with early-onset lupus, which probably reflects the contribution exerted by other comorbid conditions in the overall impact of l upus.
The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort
TLDR
There are differences in lupus phenotypes between ethnic populations, and although ethnicity was not found to be a significant independent predictor of damage accrual, low income was.
The rate and pattern of organ damage in late onset systemic lupus erythematosus.
TLDR
The occurrence of organ damage assessed by the SDI is greater in patients with late onset SLE than in younger patients and, by this criterion, lupus cannot be judged to be more benign in this age group.
Adherence To Medications In Systemic Lupus Erythematosus
TLDR
Although lack of sufficient adherence to medications appears to be a multifactorial problem, improved communication between the healthcare provider and the patient, and less complicated medication regimens, may be especially suitable interventions to improve adhere to medications.
International survey on the management of patients with SLE. II. The results of a questionnaire regarding neuropsychiatric manifestations.
TLDR
The survey found that in clinical practice, the NP manifestations currently considered to be diagnostic of primary SLE-mediated CNS involvement are not limited to those included in the American Rheumatism Association (ARA) criteria.
International survey on the management of patients with SLE. III. The results of a questionnaire regarding renal involvement.
TLDR
Some clear trends were identified in the behaviour of physicians who are "expert" in lupus patients: they perform a renal biopsy in order to charaterize the LN and repeat it when they are faced with relapse or ineffective therapy, but no trend seemed to exist for the treatment of class V LN, particularly Vm.
Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus
TLDR
Self-reported adherence in patients with rheumatoid arthritis and systemic lupus erythematosus from underserved healthcare settings appears to be more prevalent in African Americans and Hispanics than Whites; the impact of decreased adherence on outcomes could be significant and should be considered when treating patients with RA and SLE.
Late-Onset Systemic Lupus Erythematosus: A Personal Series of 47 Patients and Pooled Analysis of 714 Cases in the Literature
TLDR
The clinical pattern of late-onset SLE is characterized by a lower disease severity, and the reduced survival observed in this group seems to result mainly from the consequences of aging.
Clinical profile of patients with late-onset SLE: not a benign subgroup
TLDR
Late-onset SLE patients had a different clinical profile from the early-onsets group, but did not constitute a benign subgroup of the lupus population.
...
1
2
3
...